The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

This Fool wants to make the most of the benefits a Stocks and Shares ISA provides. He's keen on these two stocks.

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Shares of GSK PLC GSK dropped 1.38% to £16.10 Tuesday, on what proved to be an all-around favorable trading session for the ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Fulcrum Therapeutics (FULC) stock falls 70% as lead asset, losmapimod licensed from GSK (GSK) fails in a Phase 3 trial against a rare muscle disorder. Read more here.

It was a busy week for the biotech sector, with a lot of important data readouts and regulatory updates. Among these, Terns ...

Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech. Interim data suggest the vaccine candidates have an acceptable safety and ...

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...